To hear about similar clinical trials, please enter your email below
Trial Title:
Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study
NCT ID:
NCT05601388
Condition:
Colorectal Cancer
Conditions: Official terms:
Colorectal Neoplasms
Study type:
Observational [Patient Registry]
Overall status:
Unknown status
Study design:
Time perspective:
Prospective
Summary:
Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the
relative frequency of CRC is about 9-12% with high male predominance 3:1. The high
mortality rates associated with CRC is reflective of several factors including: the lack
of apparent symptoms in the early stages and the absence of cancer prevention strategies
in developing countries.
Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP
family which plays a key role in the transfer and stabilization of mRNA, cell growth, and
migration during embryogenesis. IMP3 has gained considerable interest as a
cancer-associated protein. Previous studies strongly suggest that IMP3 may represent a
valuable prognostic marker in human cancer. Its overexpression has been reported in a
variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer,
gastric cancer, liver cancer, and breast cancer
Detailed description:
Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the
relative frequency of CRC is about 9-12% with high male predominance 3:1. The high
mortality rates associated with CRC is reflective of several factors including: the lack
of apparent symptoms in the early stages and the absence of cancer prevention strategies
in developing countries.
Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP
family which plays a key role in the transfer and stabilization of mRNA, cell growth, and
migration during embryogenesis. To date, there are three known members of IMP family
proteins: IMP1, IMP2, and IMP3 . IMP3 has gained considerable interest as a
cancer-associated protein. Previous studies strongly suggest that IMP3 may represent a
valuable prognostic marker in human cancer. Its overexpression has been reported in a
variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer,
gastric cancer, liver cancer, and breast cancer
It has been reported that IMP3 expression, determined via immunohistochemistry (IHC), has
prognostic significance in CRC, recent studies revealed that IMP3 expression in tumor
cells is a marker of poor prognosis in CRC patients and promotes tumor cell
proliferation, adhesion, and invasion. Despite these observations, the IMP3 expression
and its clinicopathologic significance in human CRC needs further elucidation.
Criteria for eligibility:
Study pop:
Sixty specimens of CRC will be obtained from patients who will undergo colectomy in
General Surgery Department of Sohag Faculty of Medicine according to local Ethical
Committee regulations, to be examined in the Pathology Laboratory of the same faculty.
From October 2022, till completing the sample size.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Patients with CRC and will be underwent surgery.
Exclusion Criteria:
-
- Patients received pre-operative chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Locations:
Facility:
Name:
Faculty of Medicine
Address:
City:
Sohag
Country:
Egypt
Status:
Recruiting
Contact:
Last name:
Rasha Mokhtar, lecture
Phone:
01158408563
Start date:
October 1, 2022
Completion date:
June 1, 2023
Lead sponsor:
Agency:
Sohag University
Agency class:
Other
Source:
Sohag University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05601388
